Лечение больных с сочетанием артериальной гипертензии и ишемической болезни сердца – новые возможности

1. Карпов Ю.А., Шальнова С.А., Деев А.Д. Престариум у больных артериальной гипертонией и ишемической болезнью сердца (или факторами риска) – безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология. 2006; 6: 21–7.
2. Шальнова С.А., Деев А.Д. Характеристика пациентов высокого риска. Результаты эпидемиологической части паучно-образовательной программы ОСКАР. Кардиоваск. тер. и профилакт. 2006; 5: 58–63.
3. Верткин А.Л., Скотников А.С. Роль антагонистов кальция III поколения в лечении артериальной гипертензии у пациентов с кардиоваскулярной патологией. РМЖ. 2010; 22: 1315–21.
4. Bhatt DL et al. REACH registry Investigators. JAMA 2006; 295: 180–9.
5. Neaton JD, Wentworth D for the Multiple Risk Factor Intervention Trial Group. Serum cholesterol, blood pressure, cigarette smoking, and death fr om coronary heart disease: overall findings and differences by age for 316,099 white men. Arch Intern Med 1992; 152; 56–64.
6. Turnbull F. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overwievs of randomized trials. Lancet 2003; 362: 1527–35.
7. Blood Pressure Lowering Treatment Trialists Collaboration. Blood pressure-dependent and independent effect of agents that inhibit renin-angiotensin system. Hypertens 2007; 25: 1524–31.
8. Zanchetti A, Crepaldi G, Bond MG et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS-a randomized double-blind trial. Stroke 2004; 35: 2807–12.
9. The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
10. The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145–53.
11. Lonn E, Yusuf S, Dzavik V et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919–25.
12. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled multicentre trial (the EUROPA study). Lancet 2003; 362: 782–9.
13. Deckers JW, Goedhart DM, Boersma E et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 2006; 27: 796–801.
14. White HD. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Lancet 2003; 362: 755–7.
15. Bots ML, Remme WJ, Luscher TF et al. ACE inhibition and endothelial function: mail findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007; 21: 269–79.
16. Ceconi C, Fox K, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
17. Rodriguez-Granillo GA. Long-term effect of Perindopril on coronary atherosclerosis progression (from rhe PERindopril's Prospective Effect on Coronary a Theroslerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007; 100: 159–63.
18. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009. CD001841.
19. Kjeldsen SE, Midtbo K, Os I, Westheim A. An overview of hypertension studies with calcium antagonists. Tidsskr Nor Laegeforen 1999; 119: 1878–82.
20. Nissen SE et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–25.
21. Brener SJ et al. Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Lim it Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Am Heart J 2006; 152: 1059–63.
22. Reichardt B. Antiatherosclerotic effect of lacidipine. Pharmocotherap 1995; 6: 37–43.
23. Simon A et al. Differential effects of nifedipine and co-amilizide on the progression of early carotid wall changes. Circulation 2001; 103: 2949–54.
24. Motro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37: 1410–3.
25. Pitt B et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
26. Dahlof B et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
27. Jamerson KA et al. on behalf of the ACCOMPLISH investigators. Benazepril plus amlodipine or hydrochlorotiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–28.
28. Bertrand M et al. Сlinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.  Am Heart J 2010; 159 (5); 795–802.
29. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New Engl J Med 2004; 351: 2058–68.
30. Casin-Hemfill l, Holmvang G, Chan RC et al. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy; No answer yet (QUIET). Am J Cаrdiol 1999; 83: 43–7.
31. Brown M et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
32. Poole-Wilson PA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet 2004; 364: 849–57.
33. Pepine C et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16.
34. Bangalore S et al. Fixed-dose combinations improve medication compliance a meta-analysis. Am J Med 2007; 120: 713–9.
35. Bahl VK et al. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice. Results from the STRONG Prospective, Observational, Multicenter Study. Am J Cardiovasc Drugs 2009; 9: 136–42.
36. Hatala R Symbio: results of a longitudinal study of optimized blood pressure–lowering therapy with fixed combination perindopril/amlodipine. J Hum Hypertens article submission.

Н.Б.Перепеч 

ГОУ ВПО Санкт-Петербургская государственная медицинская академия им. И.И.Мечникова Минздравсоцразвития РФ